Nucs AI Announces Collaboration to Develop AI-driven Response Prediction

The collaboration focuses on metastatic prostate cancer and highlights the growing importance of imaging based biomarkers in helping researchers predict treatment response and improve the use of precision oncology therapies.

Under the collaboration, Nucs AI will adapt and validate its technology for new radioconjugate therapies used to treat metastatic castration-resistant prostate cancer. The goal is to develop AI models that can better predict how patients will respond to these next-generation treatments.

The work build's on Nucs AIs existing experience in predicting responses to Lutetium based therapies. By developing predictive biomarkers alongside AstraZeneca, the collaboration aims to ensure that AI driven response prediction tools evolve alongside the therapies they are designed to support.

The collaboration builds on Nucs AI’s existing platform and technologies. These include SelectPSMA, which helps predict patient outcomes for Lutetium-based PSMA radioconjugate therapies; DeepPSMA, which measures total tumor burden using PSMA PET/CT scans and TrackPSMA, which automates treatment response assessment.

Together, these tools form the foundation of Nucs AI’s precision medicine platform, helping researchers and clinicians better evaluate, monitor, and optimize radioconjugate therapies.

A new generation of cancer therapies is creating more treatment options for patients with advanced cancers. However, one of the biggest challenges in oncology is still determining which patients are most likely to benefit from a specific therapy.

Traditionally, patient selection has focused on whether a treatment target is present, rather than predicting how well an individual patient will respond. Many experts see improving response prediction as the next step in precision medicine. Nucs AI is developing its platform to help close this gap by supporting more personalized treatment decisions.

Read More:InterMedia Advertising® Appoints Derek Shipp as Vice President

"For Nucs AI, the collaboration with AstraZeneca anchors a broader strategic ambition: building a precision medicine engine, a platform for identifying and developing predictive imaging biomarker models across existing and novel therapies. This approach scales beyond a single therapy class or cancer type, extending over time across additional treatment modalities, disease contexts and therapeutic targets," said Nijat Ahmadov, CEO of Nucs AI. "Nuclear oncology, where imaging derived biomarkers connect directly to treatment selection, is the natural starting point."

About Nucs AI

Founded in 2024 by Nijat Ahmadov and Farid Yagubbayli, Nucs AI develops AI powered imaging and predictive analytics solutions for precision oncology. Its products, including DeepPSMA, SelectPSMA and TrackPSMA, help automate cancer detection, staging and treatment response evaluation, allowing clinicians to make faster and more informed decisions. Through partnerships with leading medical centers and research institution's around the world, Nucs AI is helping advance molecular imaging, and AI driven theranostics.

Read More:Rokt Appoints Bill Barton as Chief Operating Officer Overseeing People